Search Details

Word: morgan (lookup in dictionary) (lookup stats)
Dates: all
Sort By: most recent first (reverse)


Usage:

Nestle's complexity, though, comes at a price. While the company's long-term growth has outstripped that of many rivals, its margins are lower; "subpar profitability" is how Morgan Stanley analyst Sylvain Massot describes it. Its stock trades at about 15 times estimated 2002 earnings, less than that of Kraft Foods, Kellogg or Hershey Foods, which all trade at price-earnings multiples of about 20. And Nestle ranks far behind Unilever, which trades at 35. Brabeck isn't fazed. "If I had run the company based on the opinion of financial analysts, it would already have been bankrupt...

Author: /time Magazine | Title: Nestle's Quick | 11/14/2007 | See Source »

...disappointed, as you can imagine,” says Fasman. Columbia’s marching band wasn’t so sympathetic. “I mean, at the end of the day, there’s nothing I can do about it,” says Head Manager Morgan A. Robinson. “I felt bad, and I cried a little tear, but whatever.” Yeah, whatever, Columbia...way to uphold the First Amendment...

Author: By Samantha L. Connolly, CONTRIBUTING WRITER | Title: And the Band Couldn’t Play On | 11/14/2007 | See Source »

...Myers Squibb are entering a period of declining revenue growth as patents on their major drugs expire, Novartis is poised for several years of steady double-digit expansion. This year its shares in the U.S. are up about 10%--the best performance among major drug companies--even as the Morgan Stanley Capital USA Health Care Index, a basket of big drug stocks, has fallen about 25%. Novartis is the 17th most valuable company in the world, up from 27th last year...

Author: /time Magazine | Title: Drug Lord | 11/13/2007 | See Source »

That expansion was partly in preparation for the launch of a potential blockbuster drug called Zelnorm, aimed at irritable bowel syndrome, for which there are few treatments. But the FDA, expressing concern about Zelnorm's side effects, rejected the application, asking for more data. In the short term, says Morgan Stanley analyst Duncan Moore, Novartis' prospects for robust growth depend heavily on the FDA's reversing its ruling on Zelnorm and approving an anti-inflammatory drug named Prexige, which Novartis plans to submit to the agency toward the end of this year...

Author: /time Magazine | Title: Drug Lord | 11/13/2007 | See Source »

...their fancy bicycles. Economist Emmanuel Farhi says his bike is “very powerful,” and physicist Gerald Gabrielse notes that his is made of titanium. Still others, such as economist Matthew Nunn, mathematician Bret J. Benesh, English professor Elizabeth D. Lyman, and political scientists Glyn Morgan and Cindy Skach said they used Zipcars when they needed mechanized transport. “Nearly everyone I know uses them,” Morgan says of his Cambridge neighbors. The Zipcar service allows people to rent cars quickly for an hourly rate...

Author: By Maxwell L. Child, CRIMSON STAFF WRITER | Title: The Harvard Showroom Is Open | 11/13/2007 | See Source »

Previous | 96 | 97 | 98 | 99 | 100 | 101 | 102 | 103 | 104 | 105 | 106 | 107 | 108 | 109 | 110 | 111 | 112 | 113 | 114 | 115 | 116 | Next